Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.1% for ocular inflammation and pain after cataract surgery in Chinese subjects
NCT01426854Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jul 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ocular inflammation comparing Nepafenac with Placebo (2 arms). Primary endpoint: Proportion of Subjects With Clinical Cure at Day 14. Started Jul 2011; status: completed.
02
Drugs
nepafenac
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT01426854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01426854.